These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 8743336)

  • 1. Clinical pharmacokinetics of molsidomine.
    Rosenkranz B; Winkelmann BR; Parnham MJ
    Clin Pharmacokinet; 1996 May; 30(5):372-84. PubMed ID: 8743336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of molsidomine in humans.
    Ostrowski J; Resag K
    Am Heart J; 1985 Mar; 109(3 Pt 2):641-3. PubMed ID: 3838399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of molsidomine and of its active metabolite, SIN-1 (or linsidomine), in the elderly.
    Spreux-Varoquaux O; Ulmer B; Cordonnier P; Forestier A; Pays M; Ducreuzet C; Advenier C
    Fundam Clin Pharmacol; 1991; 5(6):549-56. PubMed ID: 1955198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot double-blind randomized placebo-controlled study of molsidomine 16 mg once-a-day in patients suffering from stable angina pectoris: correlation between efficacy and over time plasma concentrations.
    Messin R; Fenyvesi T; Carreer-Bruhwyler F; Crommen J; Chiap P; Hubert P; Dubois C; Famaey JP; Géczy J
    Eur J Clin Pharmacol; 2003 Jul; 59(3):227-32. PubMed ID: 12734607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of linsidomine (SIN 1) after single and multiple intravenous short infusions in patients with renal insufficiency.
    Sennesael J; Verbeelen D; Degré S; Unger P; Stolear JC; Ostrowski J; von Hattingberg HM; Gaertner W
    Int J Clin Pharmacol Ther Toxicol; 1993 Nov; 31(11):533-41. PubMed ID: 8294165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Human pharmacokinetics of molsidomine].
    Singlas E; Martre H
    Ann Cardiol Angeiol (Paris); 1983 Dec; 32(8):503-9. PubMed ID: 6364946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease.
    Bramer SL; Forbes WP; Mallikaarjun S
    Clin Pharmacokinet; 1999; 37 Suppl 2():1-11. PubMed ID: 10702882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefetamet pivoxil clinical pharmacokinetics.
    Blouin RA; Stoeckel K
    Clin Pharmacokinet; 1993 Sep; 25(3):172-88. PubMed ID: 8222459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of dipyrone and its metabolites.
    Levy M; Zylber-Katz E; Rosenkranz B
    Clin Pharmacokinet; 1995 Mar; 28(3):216-34. PubMed ID: 7758252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of molsidomine and its active metabolite, linsidomine, in patients with liver cirrhosis.
    Spreux-Varoquaux O; Doll J; Dutot C; Grandjean N; Cordonnier P; Pays M; Andrieu J; Advenier C
    Br J Clin Pharmacol; 1991 Sep; 32(3):399-401. PubMed ID: 1777378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics.
    Bramer SL; Forbes WP
    Clin Pharmacokinet; 1999; 37 Suppl 2():13-23. PubMed ID: 10702883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between pharmacokinetics and pharmacodynamics of molsidomine and its metabolites in humans.
    Meinertz T; Brandstätter A; Trenk D; Jähnchen E; Ostrowski J; Gärtner W
    Am Heart J; 1985 Mar; 109(3 Pt 2):644-8. PubMed ID: 3838400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of an extended-release dosage form of molsidomine in patients with coronary heart disease.
    Ostrowski J; Gaul G; Voegele D; Brockmeier D; Resag K
    Eur J Clin Pharmacol; 1985; 28(5):611-3. PubMed ID: 3899679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of combination therapy (isosorbide dinitrate and molsidomine) on the incidence of angina pectoris in patients with coronary heart disease].
    Ciopor M; Fischer A; Turina J; Hess OM
    Praxis (Bern 1994); 1997 Nov; 86(47):1849-53. PubMed ID: 9480502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of prazosin.
    Jaillon P
    Clin Pharmacokinet; 1980; 5(4):365-76. PubMed ID: 6994981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of epanolol (ICI 141,292) in healthy young volunteers and comparative data in elderly patients with angina and subjects with renal or hepatic impairment.
    Cockshott ID
    Drugs; 1989; 38 Suppl 2():10-7. PubMed ID: 2575975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacological basis of therapy with molsidomine].
    Bassenge E
    Herz; 1982 Oct; 7(5):296-306. PubMed ID: 6897544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-ischemic effect of 8 mg molsidomin in retard form].
    Blasini R; Brügmann U; Rudolph W
    Herz; 1984 Dec; 9(6):346-52. PubMed ID: 6392050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Coronary dilatation after intracoronary administration of SIN-1 and intravenous molsidomine administration].
    Hug J; Hasenfuss G; Wollschläger H; Just HJ; Bonzel T
    Med Klin (Munich); 1994 Jul; 89 Suppl 2():34-7. PubMed ID: 7968899
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.
    He G; Massarella J; Ward P
    Clin Pharmacokinet; 1999 Dec; 37(6):471-84. PubMed ID: 10628898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.